Stay updated with breaking news from Dimer Binding Assay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have... | December 29, 2022
Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have... | December 1, 2022
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in
Press release content from Business Wire. The AP news staff was not involved in its creation.
STAFFORD, Texas--(BUSINESS WIRE)--Apr 10, 2021-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the âCompanyâ), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is critical to developing dosing and booster treatment strategies that are designed to achieve and sustai...